British Journal of Cancer - Comment on: /`Evaluation of chemoresponse assays as predictive markers/' Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, June 26, 2015

British Journal of Cancer - Comment on: /`Evaluation of chemoresponse assays as predictive markers/'



Comment  open access

DJS received compensation for consulting work from Helomics Corporation. MJG, SLB and CT are paid employees of Helomics Corporation.

.....We agree with Korn and Freidlin (2015) that evaluating the predictive value of chemoresponse assays is challenging. As with any observational study, it is impossible to entirely exclude bias, and a definitive answer relies on randomised clinical trials. However, randomised trials to evaluate predictive markers are highly challenging in rare tumour types such as recurrent ovarian cancer, particularly when a large number of treatment options are available. The length of time for patient accrual alone is likely to obfuscate clinical utility. Thus, observational studies and other non-randomised prospective studies must continue to have an important role in evaluating chemoresponse assays in this cancer type. We feel that in the appropriate circumstance, our proposed match/mismatch analysis can provide helpful information regarding an assay’s potential prognostic and/or predictive value.


References

  1. Korn EL, Freidlin B (2015) Evaluation of chemoresponse assays as predictive markers. Br J Cancer 112: 621–623. | Article | PubMed | ISI |
  2. National Comprehensive Cancer Network (2014) NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer: Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2014.
  3. Rutherford T, Orr J Jr, Grendys E Jr, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ (2013) A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol 131: 362–367. | Article | PubMed | ISI |
  4. Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL (2014) Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. Br J Cancer 111: 843–850. | Article | PubMed | ISI |

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.